Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma

European Journal of Haematology

Volumn 74, Issue 1, 2005, Pages 40-46

  Schutt P ^a   Ebeling, P ^a   Buttkereit, U ^a   Brandhorst, D ^a   Opalka, B ^a   Hoiczyk, M ^a   Flasshove, M ^a   Hense, J ^a   Bojko, P ^a   Metz, K ^a   Moritz, T ^a   Seeber, S ^a   Nowrousian, M R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Anthracycline; Chemotherapy; Multiple myeloma; Thalidomide; VED

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG INDICATION; DRUG RESPONSE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PARESTHESIA; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SEPTIC SHOCK; SIDE EFFECT; SINUS BRADYCARDIA; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; THALIDOMIDE; VINCRISTINE;

EID: 19944430150     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00349.x     Document Type: Article

References (43)

1. SINGHAL S, MEHTA J, DESIKAN R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
2. VACCA A, RIBATTI D, RONCALI L, RANIERI G, SERIO G, SILVESTRIS F, DAMMACCO F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-508.
3. D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
4. BARLOGIE B, DESIKAN R. EDDLEMON P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-494.
5. PARMAN T, WILEY MJ, WELLS PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999;5:582-585.
6. HASLETT PA, CORRAL LG, ALBERT M, KAPLAN G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-1892.
7. DAVIES FE, RAJE N, HIDESHIMA T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
8. HIDESHIMA T, CHAUHAN D, SHIMA Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-2950.
9. GEITZ H, HANDT S, ZWINGENBERGER K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-221.
10. RICHARDSON PG, SCHLOSSMAN RL, WELLER E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-3067.
11. WEBER D, RANKIN K, GAVINO M, DELASALLE K, ALEXANIAN R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-19.
12. RAJKUMAR SV, HAYMAN S, GERTZ MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-4323.
13. DIMOPOULOS MA, ZERVAS K, KOUVATSEAS G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001;12:991-995.
14. ALEXANIAN R, BARLOGIE B, DIXON D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11.
15. ALEXANIAN R, DIMOPOULOS MA, DELASALLE K, BARLOGIE B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-890.
16. LEE CK, BARLOGIE B, MUNSHI N, ZANGARI M, FASSAS A, JACOBSON J, van RHEE F, COTTLER-FOX M, MUWALLA F, TRICOT G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-2739.
17. KROPFF MH, LANG N, BISPING G et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003;122:607-616.
18. BARLOGIE B, SMITH L, ALEXANIAN R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-1356.
19. BARLOGIE B, JAGANNATH S, DESIKAN KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
20. ANDERSON H, SCARFFE JH, RANSON M, YOUNG R, WIERINGA GS, MORGENSTERN GR, FITZSIMMONS L, RYDER D. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995;71:326-330.
21. SEGEREN CM, SONNEVELD P, VAN DER HOLT B et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999;105:127-130.
22. SAMSON D, GAMINARA E, NEWLAND A et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;2:882-885.
23. LOKHORST HM, MEUWISSEN OJ, BAST EJ, DEKKER AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989;71:25-30.
24. DIMOPOULOS MA, POULI A, ZERVAS K et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003;14:1039-1044.
25. FOSSA A, MUER M, KASPER C, WELT A, SEEBER S, NOWROUSIAN MR. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Leukemia 1998;12:422-426.
26. ROBERT J. Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 1993;45(Suppl 2):20-30.
27. ZERVAS K, DIMOPOULOS MA, HATZICHARISSI E, ANAGNOSTOPOULOS A, PAPAIOANNOU M, MITSOULI C, PANAGIOTIDIS P, KORANTZIS J, TZILIANOS M, MANIATIS A. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004;15:134-138.
28. BLADE J, SAMSON D, REECE D, APPERLEY J, BJORKSTRAND B, GAHRTON G, GERTZ M, GIRALT S, JAGANNATH S, VESOLE D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
29. KAPLAN EL, MEIER P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
30. COX DR, MCCULLAGH P. Some aspects of analysis of covariance. Biometrics 1982;38:541-561.
31. JULIUSSON G, CELSING F, TURESSON I, LENHOFF S, ADRIANSSON M, MALM C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
32. KNELLER A, RAANANI P, HARDAN I, AVIGDOR A, LEVI I, BERKOWICZ M, BEN-BASSAT I. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br J Haematol 2000;108:391-393.
33. RAJKUMAR SV, GERTZ MA, LACY MQ et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17:775-779.
34. MOEHLER TM, NEBEN K, BENNER A, EGERER G, KRASNIQI F, HO AD, GOLDSCHMIDT H. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001;98:3846-3848.
35. HUSSEIN MA. Doxil, vincristine, decadron and thalidomide (DVD-T) for newly diagnosed, and relapsed/refractory multiple myeloma: response to therapy and supportive care issues. Hematol J 2003;4(Suppl 1):S4.
36. ALEXANIAN R, WEBER D, GIRALT S, DIMOPOULOS M, DELASALLE K, SMITH T, CHAMPLIN R. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001;27:1037-1043.
37. DAVIES FE, FORSYTH PD, RAWSTRON AC et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001;112:814-819.
38. AHMAD I, ISLAM T, CHANAN-KHAN A, HAHN T, WENTLING D, BECKER JL, MCCARTHY PL Jr, ALAM AR. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant 2002;29:577-580.
39. GHOBRIAL IM, DISPENZIERI A, BUNDY KL et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003;32:587-592.
40. ZANGARI M, ANAISSIE E, BARLOGIE B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-1615.
41. OSMAN K, COMENZO R, RAJKUMAR SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001;344:1951-1952.
42. ZANGARI M, SIEGEL E, BARLOGIE B, ANAISSIE E, SAGHAFIFAR F, FASSAS A, MORRIS C, FINK L, TRICOT G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168-1171.
43. TSO E, BAZ R, MARCHANT K, ELSON P, SRKALOVIC G, KARAM MA, REED J, ANDRESEN S, HUSSEIN MA. Aspirin prophylaxis during treatment of multiple myeloma using liposomal doxorubicin, vincristine, decreased-frequency dexamethasone and thalidomide (DVd-T) decreases posttreatment thrombosis. Proc Am Soc Clin Oncol 2003;22:584 (abstr 2349).